Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
On June 12, NIH’s National Center for Advancing Translational Sciences (NCATS) will disclose its list of molecules for repurposing under a joint agency-industry pilot program. The initiative, Discovering New Therapeutic Uses for Existing Molecules, was announced last month. Pfizer, AstraZeneca, and Eli Lilly have agreed to allow researchers to study some of their shelved compounds, in hopes of advancing the understanding of various disease mechanism as well as finding new indications. Additional pharma companies may join, increasing the number of shelved compounds available for study.